The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.

The present disclosure provides proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.

The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy. IL10 agonists disclosed herein comprise an IgG Fc domain, a linker moiety, and an IL10 moiety.

The present invention relates to a novel immunoglobulin Fc domain variant protein and use thereof, and when expressed in the form of a fusion protein with another biologically active protein, an immunoglobulin Fc domain variant protein according to an embodiment of the present invention can prolong the half-life in vivo of the biologically active protein as well as effectively suppress effector functions such as ADCC or CDC to minimize unexpected side effects.

There is provided a salt-tolerant Lactobacillus having high foodstuff suitability, being easily produced, and having an immunostimulatory action. Salt-tolerant Lactobacillus having an immunostimulatory action with viability and activation potency of B cells.

A nucleic acid construct and an immune cell, which harbor nucleic acids encoding a CAR and nucleic acids encoding at least one anti-inflammatory or immunosuppressant protein and methods of using the same in treatment or amelioration of inflammation or immune-mediated autoimmunity are described.

The present invention provides fusion proteins including an autoimmune antigen, an allergen antigen or an alloantigen, and an anti-inflammatory cytokine. Compositions and methods including the fusion proteins are also provided.

The present invention is directed to methods of inducing a phenotypic change in a population of monocytes and; or macrophages. The method includes administering to the population of monocytes and/or macrophages, a macrophage stimulating agent coupled to a carrier molecule, wherein the carrier molecule facilitates macropinocytic uptake of the agent by monocytes and macrophages in the population and is defective in neonatal Fc receptor binding, wherein the administering induces a phenotypic change in the monocytes and macrophages in the population.

Provided is a protein comprising an antibody or antigen-binding fragment and an interleukin molecule operably linked to the antibody or antigen-binding fragment. The antibody or antigen-binding fragment specifically binds to an immune checkpoint protein. The interleukin molecule is IL-10.

The present invention relates to a novel IL-10 variant protein and use thereof, and more particularly, to a novel IL-10 variant protein whose immune stimulatory activity is inhibited and yield of production is increased by forming monomers when expressed.